8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Nov 4, 2025·SEC
Taysha Gene Therapies, Inc.(TSHA)Earnings, Financials & Key Ratios
TSHA•NASDAQ
$6.67
$1.92B mkt cap·Price updated May 7, 2026
AboutTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.Show more
- Revenue$10M+17.3%
- EBITDA-$109M-21.2%
- Net Income-$109M-22.1%
- EPS (Diluted)-0.34+5.6%
- Gross Margin88.28%-11.7%
- EBITDA Margin-1118.93%-3.4%
- Operating Margin-1130.65%-3.0%
- Net Margin-1115.27%-4.1%
- ROE-68.45%+43.9%
- Debt/Equity0.07-91.7%
- Interest Coverage-1753.94-100.6%
TSHA Key Insights
Taysha Gene Therapies, Inc. (TSHA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 89 (top 11%)
✗Weaknesses
- ✗Profits declining 20.4% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 27.8% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TSHA Price & Volume
Taysha Gene Therapies, Inc. (TSHA) stock price & volume — 10-year historical chart
Loading chart...
TSHA Growth Metrics
Taysha Gene Therapies, Inc. (TSHA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years57.49%
TTM3.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-49.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.29%
Return on Capital
10 Years-69.82%
5 Years-76.95%
3 Years-63.12%
Last Year-49.01%
TSHA Recent Earnings
Taysha Gene Therapies, Inc. (TSHA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (70%)
Q2 2026Latest
May 6, 2026EPS
$0.12
Est $0.10
-20.0%
Revenue
—
Est $755,556
Q2 2026
Mar 19, 2026EPS
$0.08
Est $0.11
+27.3%
Revenue
$5M
Est $2M
+144.5%
Q4 2025
Nov 4, 2025EPS
$0.09
Est $0.09
+0.0%
Revenue
—
Est $2M
Q3 2025
Aug 12, 2025EPS
$0.09
Est $0.07
-28.6%
Revenue
$2M
Est $2M
+14.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.12vs $0.10-20.0% | —vs $755,556 |
| Q2 2026 | Mar 19, 2026 | $0.08vs $0.11+27.3% | $5Mvs $2M+144.5% |
| Q4 2025 | Nov 4, 2025 | $0.09vs $0.09+0.0% | —vs $2M |
| Q3 2025 | Aug 12, 2025 | $0.09vs $0.07-28.6% | $2Mvs $2M+14.9% |
Based on last 12 quarters of dataView full earnings history →
TSHA Peer Comparison
Taysha Gene Therapies, Inc. (TSHA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 2.18B | 20.80 | -2.92 | 15.58% | 2.98% | 4.89% | 0.91 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 SGMO | 21.54M | 0.10 | -0.21 | -67.2% | -331.28% | -8.14% | 1.34 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 |
Compare TSHA vs Peers
Taysha Gene Therapies, Inc. (TSHA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TSHA Income Statement
Taysha Gene Therapies, Inc. (TSHA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 2.5M | 15.45M | 8.33M | 9.77M | 7.47M |
| Revenue Growth % | - | - | - | - | 517.55% | -46.07% | 17.28% | 3.42% |
| Cost of Goods Sold | 0 | 9K | 0 | 2.49M | 0 | 0 | 1.15M | 585K |
| COGS % of Revenue | - | - | - | 99.4% | - | - | 11.72% | - |
| Gross Profit | 0▲ 0% | -9K▲ 0% | 0▲ 100.0% | 15K▲ 0% | 15.45M▲ 102913.5% | 8.33M▼ 46.1% | 8.63M▲ 3.5% | 6.89M▲ 0% |
| Gross Margin % | - | - | - | 0.6% | 100% | 100% | 88.28% | 92.17% |
| Gross Profit Growth % | - | - | 100% | - | 102913.53% | -46.07% | 3.54% | - |
| Operating Expenses | 1.11M | 42.99M | 173.27M | 126.04M | 87.89M | 99.79M | 119.13M | 139.45M |
| OpEx % of Revenue | - | - | - | 5037.65% | 568.83% | 1197.55% | 1218.93% | - |
| Selling, General & Admin | 128K | 11.1M | 41.32M | 34.87M | 30.05M | 28.95M | 32.72M | 35.39M |
| SG&A % of Revenue | - | - | - | 1393.81% | 194.47% | 347.45% | 334.83% | - |
| Research & Development | 987K | 31.89M | 131.94M | 91.17M | 56.78M | 66M | 86.4M | 104.06M |
| R&D % of Revenue | - | - | - | 3643.84% | 367.47% | 792.04% | 884.1% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 1.06M | 4.84M | 0 | 0 |
| Operating Income | -1.11M▲ 0% | -43M▼ 3756.7% | -173.27M▼ 302.9% | -126.03M▲ 27.3% | -72.44M▲ 42.5% | -91.46M▼ 26.3% | -110.5M▼ 20.8% | -132.56M▲ 0% |
| Operating Margin % | - | - | - | -5037.05% | -468.83% | -1097.55% | -1130.65% | -1774.37% |
| Operating Income Growth % | - | -3756.68% | -302.93% | 27.26% | 42.52% | -26.26% | -20.82% | - |
| EBITDA | 3.35M | -42.99M | -172.78M | -123.54M | -71.07M | -90.21M | -109.35M | -131.7M |
| EBITDA Margin % | - | - | - | -4937.65% | -459.96% | -1082.61% | -1118.93% | -1762.83% |
| EBITDA Growth % | - | -1385.29% | -301.87% | 28.5% | 42.47% | -26.94% | -21.22% | -50.78% |
| D&A (Non-Cash Add-back) | 4.46M | 9K | 492K | 2.49M | 1.37M | 1.25M | 1.15M | 862K |
| EBIT | -4.46M | -59.98M | -173.09M | -162.22M | -106.57M | -89.2M | -110.5M | -87.88M |
| Net Interest Income | 0 | 21K | -1.26M | -3.55M | -1.43M | 6.84M | 9.16M | 7.85M |
| Interest Income | 0 | 49K | 172K | 249K | 3.57M | 6.94M | 9.22M | 10.48M |
| Interest Expense | 0 | 28K | 1.43M | 3.8M | 5M | 102K | 63K | 35K |
| Other Income/Expense | 0 | -17.01M | -1.26M | -39.99M | -39.13M | 2.16M | 1.5M | 2.69M |
| Pretax Income | -1.11M▲ 0% | -60.01M▼ 5282.2% | -174.52M▼ 190.8% | -166.01M▲ 4.9% | -111.57M▲ 32.8% | -89.3M▲ 20.0% | -109M▼ 22.1% | -129.88M▲ 0% |
| Pretax Margin % | - | - | - | -6635.25% | -722.06% | -1071.62% | -1115.27% | -1738.4% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.11M▲ 0% | -43M▼ 3756.5% | -174.52M▼ 305.9% | -166.01M▲ 4.9% | -111.57M▲ 32.8% | -89.3M▲ 20.0% | -109M▼ 22.1% | -129.88M▲ 0% |
| Net Margin % | - | - | - | -6635.25% | -722.06% | -1071.62% | -1115.27% | -1738.4% |
| Net Income Growth % | - | -3756.5% | -305.87% | 4.88% | 32.8% | 19.96% | -22.06% | -49.69% |
| Net Income (Continuing) | -1.11M | -60.01M | -174.52M | -166.01M | -111.57M | -89.3M | -109M | -129.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03▲ 0% | -3.40▼ 11195.7% | -4.64▼ 36.5% | -3.78▲ 18.5% | -0.96▲ 74.6% | -0.36▲ 62.5% | -0.34▲ 5.6% | -0.35▲ 0% |
| EPS Growth % | - | -11195.68% | -36.47% | 18.53% | 74.6% | 62.5% | 5.56% | -7.29% |
| EPS (Basic) | -0.03 | -3.40 | -4.64 | -3.78 | -0.96 | -0.36 | -0.34 | - |
| Diluted Shares Outstanding | 36.99M | 17.67M | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M | 366.63M |
| Basic Shares Outstanding | 36.99M | 17.67M | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M | 366.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TSHA Balance Sheet
Taysha Gene Therapies, Inc. (TSHA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15K | 257.88M | 159.6M | 96.42M | 149.87M | 142.13M | 324.65M | 282.25M |
| Cash & Short-Term Investments | 0 | 251.25M | 149.1M | 87.88M | 143.94M | 139.04M | 319.77M | 276.58M |
| Cash Only | 0 | 251.25M | 149.1M | 87.88M | 143.94M | 139.04M | 319.77M | 276.58M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 15K | 331K | 6.63M | 1.19M | 3.42M | 892K | 4.88M | 5.67M |
| Total Non-Current Assets | 15K | 1M | 54.35M | 29.86M | 22.86M | 18.23M | 18.67M | 18.1M |
| Property, Plant & Equipment | 0 | 287K | 50.61M | 25.91M | 20.41M | 15.87M | 16.18M | 15.61M |
| Fixed Asset Turnover | - | - | - | 0.10x | 0.76x | 0.53x | 0.60x | 0.49x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 2.64M | 0 | 0 | 0 | 2.31M | 2.31M |
| Other Non-Current Assets | 15K | 715K | 1.11M | 3.95M | 2.46M | 2.37M | 183K | 7.35M |
| Total Assets | 15K▲ 0% | 258.88M▲ 1725773.3% | 213.96M▼ 17.4% | 126.28M▼ 41.0% | 172.73M▲ 36.8% | 160.36M▼ 7.2% | 343.32M▲ 114.1% | 300.35M▲ 0% |
| Asset Turnover | - | - | - | 0.02x | 0.09x | 0.05x | 0.03x | 0.02x |
| Asset Growth % | - | 1725773.33% | -17.35% | -40.98% | 36.79% | -7.16% | 114.09% | 373.15% |
| Total Current Liabilities | 150K | 7.13M | 51.75M | 62.79M | 36.76M | 26.23M | 26.55M | 20.1M |
| Accounts Payable | 0 | 1.99M | 21.76M | 10.95M | 6.37M | 3.59M | 6.28M | 4.56M |
| Days Payables Outstanding | - | 80.87K | - | 1.61K | - | - | 2K | 3.74K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 33.56M | 18.11M | 9.77M | 0 | 5.49M |
| Other Current Liabilities | 21K | 1.86M | 4.13M | 4.63M | 4.99M | 6.43M | 10.85M | 15.53M |
| Current Ratio | 0.10x | 36.17x | 3.08x | 1.54x | 4.08x | 5.42x | 12.23x | 12.23x |
| Quick Ratio | 0.10x | 36.17x | 3.08x | 1.54x | 4.08x | 5.42x | 12.23x | 12.23x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 450K | 66.83M | 62.54M | 61.04M | 62.61M | 69.83M | 68.31M |
| Long-Term Debt | 0 | 0 | 37.19M | 37.97M | 40.51M | 43.94M | 18.17M | 17.77M |
| Capital Lease Obligations | 0 | 0 | 25.9M | 20.44M | 18.95M | 17.36M | 0 | 33.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 450K | 3.73M | 4.13M | 1.58M | 1.31M | 51.66M | 105.12M |
| Total Liabilities | 150K | 7.58M | 118.57M | 125.33M | 97.79M | 88.84M | 96.38M | 88.41M |
| Total Debt | 0 | 0 | 63.09M | 59.93M | 61.11M | 63.18M | 18.17M | 17.77M |
| Net Debt | 0 | -251.25M | -86.01M | -27.95M | -82.83M | -75.86M | -301.6M | -258.81M |
| Debt / Equity | - | - | 0.66x | 63.15x | 0.82x | 0.88x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.13x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 1.97x |
| Interest Coverage | - | -2142.25x | -121.21x | -42.71x | -21.32x | -874.47x | -1753.94x | -2510.94x |
| Total Equity | -135K▲ 0% | 251.3M▲ 186249.6% | 95.38M▼ 62.0% | 949K▼ 99.0% | 74.94M▲ 7796.4% | 71.53M▼ 4.6% | 246.94M▲ 245.2% | 211.94M▲ 0% |
| Equity Growth % | - | 186249.63% | -62.04% | -99.01% | 7796.42% | -4.55% | 245.25% | 805.27% |
| Book Value per Share | -0.00 | 14.23 | 2.53 | 0.02 | 0.65 | 0.29 | 0.77 | 0.58 |
| Total Shareholders' Equity | -135K | 251.3M | 95.38M | 949K | 74.94M | 71.53M | 246.94M | 211.94M |
| Common Stock | 0 | 0 | 0 | 1K | 2K | 2K | 3K | 3K |
| Retained Earnings | -1.11M | -61.13M | -235.65M | -401.44M | -513.01M | -602.3M | -711.3M | -753.71M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | -4.03M | -192K | 985K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TSHA Cash Flow Statement
Taysha Gene Therapies, Inc. (TSHA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 135K | -30.73M | -117.04M | -88.39M | -73.02M | -81.22M | -93.09M | -93.09M |
| Operating CF Margin % | - | - | - | -3532.77% | -472.58% | -974.74% | -952.52% | - |
| Operating CF Growth % | - | -22862.22% | -280.88% | 24.48% | 17.39% | -11.24% | -14.61% | -137.25% |
| Net Income | -1.11M | -60.01M | -174.52M | -166.01M | -111.57M | -89.3M | -109M | -129.88M |
| Depreciation & Amortization | 0 | 9K | 492K | 1.17M | 1.37M | 1.25M | 1.15M | 1.3M |
| Stock-Based Compensation | 0 | 3.35M | 18.18M | 18.04M | 7.91M | 13.1M | 13.3M | 15.55M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 710K | 26.03M | 10.14M | 39.89M | 47.28M | 6.19M | 6.83M | -60K |
| Working Capital Changes | 540K | -111K | 28.67M | 18.52M | -18.01M | -12.47M | -5.37M | 1.13M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 1.96M | 14.49M | -7.8M | -2.29M | -2.92M | -153K | 2.16M |
| Cash from Investing | 0 | -9.08M | -21.55M | -24.93M | -7.35M | -363K | -604K | -3.26M |
| Capital Expenditures | 0 | -82K | -21.55M | -24.87M | -3.87M | -374K | -738K | -384K |
| CapEx % of Revenue | - | - | - | 993.96% | 25.04% | 4.49% | 7.55% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -9M | 0 | -61K | -3.48M | 11K | 134K | -2.87M |
| Cash from Financing | 0 | 291.06M | 39.08M | 52.1M | 136.39M | 76.68M | 274.59M | 275.35M |
| Debt Issued (Net) | 0 | 0 | 39.96M | 0 | -3.45M | 0 | 9.24M | 0 |
| Equity Issued (Net) | 0 | 291.06M | -360K | 53.24M | 140.79M | 76.78M | 265.69M | 265.61M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -173K |
| Other Financing | 0 | 0 | -514K | -1.15M | -947K | -96K | -337K | 9.74M |
| Net Change in Cash | 135K▲ 0% | 251.25M▲ 186013.3% | -99.51M▼ 139.6% | -61.22M▲ 38.5% | 56.02M▲ 191.5% | -4.9M▼ 108.8% | 180.9M▲ 3788.7% | 160.15M▲ 0% |
| Free Cash Flow | 135K▲ 0% | -39.81M▼ 29589.6% | -138.6M▼ 248.1% | -113.26M▲ 18.3% | -80.39M▲ 29.0% | -81.6M▼ 1.5% | -93.83M▼ 15.0% | -112.33M▲ 0% |
| FCF Margin % | - | - | - | -4526.74% | -520.27% | -979.23% | -960.07% | -1503.57% |
| FCF Growth % | - | -29589.63% | -248.13% | 18.28% | 29.02% | -1.51% | -14.99% | -33.63% |
| FCF per Share | 0.00 | -2.25 | -3.68 | -2.58 | -0.69 | -0.33 | -0.29 | -0.29 |
| FCF Conversion (FCF/Net Income) | -0.12x | 0.71x | 0.67x | 0.53x | 0.65x | 0.91x | 0.85x | 0.86x |
| Interest Paid | 0 | 28K | 641K | 2.77M | 4.95M | 5.28M | 0 | 1.36M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TSHA Key Ratios
Taysha Gene Therapies, Inc. (TSHA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -34.24% | -100.68% | -344.67% | -294.04% | -121.94% | -68.45% | -56.07% |
| Return on Invested Capital (ROIC) | - | -2758.74% | - | - | - | - | 345.12% |
| Gross Margin | - | - | 0.6% | 100% | 100% | 88.28% | 92.17% |
| Net Margin | - | - | -6635.25% | -722.06% | -1071.62% | -1115.27% | -1738.4% |
| Debt / Equity | - | 0.66x | 63.15x | 0.82x | 0.88x | 0.07x | 0.07x |
| Interest Coverage | -2142.25x | -121.21x | -42.71x | -21.32x | -874.47x | -1753.94x | -2510.94x |
| FCF Conversion | 0.71x | 0.67x | 0.53x | 0.65x | 0.91x | 0.85x | 0.86x |
| Revenue Growth | - | - | - | 517.55% | -46.07% | 17.28% | 3.42% |
TSHA SEC Filings & Documents
Taysha Gene Therapies, Inc. (TSHA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TSHA Frequently Asked Questions
Taysha Gene Therapies, Inc. (TSHA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Taysha Gene Therapies, Inc. (TSHA) reported $7.5M in revenue for fiscal year 2025.
Taysha Gene Therapies, Inc. (TSHA) grew revenue by 17.3% over the past year. This is strong growth.
Taysha Gene Therapies, Inc. (TSHA) reported a net loss of $129.9M for fiscal year 2025.
Dividend & Returns
Taysha Gene Therapies, Inc. (TSHA) has a return on equity (ROE) of -68.5%. Negative ROE indicates the company is unprofitable.
Taysha Gene Therapies, Inc. (TSHA) had negative free cash flow of $112.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More TSHA
Taysha Gene Therapies, Inc. (TSHA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates